Ministry of Health confirms: No recalls on Valsartan products
There are no recalls on Valsartan products currently procured through the Ministry of Health, Trinidad and Tobago for the public and private sector.
On July 17, 2018 the United States Food and Drugs Administration (U.S. FDA) released an update alerting members of the public of a voluntary recall of several drug products containing the active ingredient Valsartan.
The recalled products were found to contain the impurity and probable human carcinogen, N-nitrosodiumethylamine (NDMA). However, none of the Valsartan products registered for use in Trinidad and Tobago are on the U.S. FDA list of recalled preparations.
Further, Valsartan has not been selected by cardiovascular specialists for use in the public system for the last two tender periods (2017/2018 and 2018/2019).